Dechra receives approval for Amoxicillin and Clavulanate Potassium Oral Suspension Drops
Thursday, October 21, 2021
Approval expands Dechra’s growing companion animal products (CAP) range of anti-infectives.
Amoxicillin and Clavulanate Potassium Oral Suspension Drops is the latest addition to Dechra’s broad anti-infective dermatology portfolio that includes systemic and topical products such as Cefpoderm® (cefpodoxime proxetil) Tablets, Clavacillin® (amoxicillin trihydrate/clavulanate potassium) Veterinary Tablets, Enroquin® Flavored Tablets (enrofloxacin), Marboquin® (marbofloxacin) Tablets, Animax® Ointment (nystatin-neomycin sulfate-thiostrepton-triamcinolone acetonide), GentaCalm® Topical Spray (gentamicin sulfate and betamethasone valerate), Muricin® (mupirocin ointment 2%) and our recent acquisition of Osurnia® (florfenicol, terbinafine, betamethasone acetate) Otic gel for dogs.
Mike Eldred, President of North America Operations, commented: “The upcoming launch of Amoxicillin and Clavulanate Potassium Oral Suspension will offer flexible dosing options for veterinarians, while extending our Amoxicillin and Clavulanate Potassium product portfolio and further solidifies Dechra’s position as a market leader in companion animal anti-infectives. Dechra continues to lead the way in product development, portfolio expansions, and acquisitions. We are committed to providing veterinarians with cost savings and loyalty options through our Dechra Rewards Program and unsurpassed technical support and educational opportunities.”
The product will soon be available for veterinarians to purchase through select veterinary distributors.
About Dechra
Dechra’s endocrinology line includes Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), and Felimazole® Coated Tablets (methimazole). Dechra’s dermatology products include oral anti-infectives, including Marboquin® (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, and a full line of topical therapies, including Osurnia® (florfenicol-terbinafine-betamethasone acetate). Dechra also offers NSAIDs and Phycox® joint supplements.
For questions or further information, please contact Mike Eldred or Doug Hubert:
Mike Eldred, President, North American Operations, Dechra Veterinary Products, Mike.Eldred@Dechra.com
Doug Hubert, Vice President, Sales and Marketing, Dechra Veterinary Products, Doug.Hubert@Dechra.com